Algernon Pharmaceuticals has entered an Investigator-Initiated Clinical Trial Agreement with Yale University to investigate multiple intravenous doses of DMT for the treatment of depression.
Beckley Psytech has entered into a definitive agreement to acquire clinical-stage life science company, Eleusis Therapeutics Limited, in an all-equity transaction.
HMNC Brain Health has raised €14.3m in a funding series, raised from existing investors, including Carsten Maschmeyer, the Jahr Group and Guntard Gutmann.
Small Pharma has had its second United States patent granted by the United States Patent Office.
Clairvoyant has received regulatory approval for its Phase 2 trial investigating psilocybin for the treatment of alcohol use disorder (AUD).
Awakn CEO, Anthony Tennyson, spoke to Psychedelic Health about the company’s plans to make ketamine therapy accessible to US patients.
LOVE Pharma’s trial will be exploring psilocybin-assisted therapy for cannabis use disorder (CUD), with Johns Hopkins University School of Medicine’s Dr Albert Garcia-Romeu serving as head...
Silo Wellness has confirmed it has acquired Dyscovry Science – a Toronto-based biotechnology company focused on biosynthetic manufacturing of psilocybin and its derivatives, targeting irritable bowel...
A wholly-owned subsidiary of HYTN Innovations Inc.,
The European Psychiatric Association (EPA) is joining the Psychedelic Access and Research European Alliance (PAREA) as a full member.